Last reviewed · How we verify
NCT05964049
pBFS Guided rTMS Therapy for Treatment-resistant Obsessive-Compulsive Disorder
NA trial testing active rTMS treatment in Obsessive-Compulsive Disorder in 30 participants. Status unknown.
20 July 2024
Quick facts
| Lead sponsor | Changping Laboratory |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 16 July 2023 |
| Primary completion | 20 July 2024 |
| Estimated completion | 20 October 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- active rTMS treatment
- sham rTMS treatment
Conditions studied
- Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →
- OCD — all drugs for OCD →
Sponsor
Changping Laboratory
Who can join
Adults 18 to 65, any sex, with Obsessive-Compulsive Disorder or OCD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators aim to evaluate the safety and efficacy of pBFS-guided rTMS therapy targeting DLPFC for patients with treatment-resistant Obsessive-Compulsive Disorder.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05964049
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of active rTMS treatment
Trials testing the same drug.
- NCT06350396 — pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression · NA · recruiting
- NCT05964062 — pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Obsessive-Compulsive Disorder · NA · unknown
- NCT05948839 — pBFS Guided rTMS Over DMPFC for Treatment-Resistant Depression · NA · unknown
- NCT03159351 — The Antidepressant Effects of rTMS After Ischemic Stroke · NA · unknown
Other recruiting trials for Obsessive-Compulsive Disorder
Currently open trials in the same condition.
- NCT06575075 — Pilot Study of RR-HNK in OCD · Phase 1, PHASE2 · recruiting
- NCT05783817 — MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) · Phase 2 · recruiting
- NCT07065669 — Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation · NA · recruiting
- NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
- NCT07000812 — EEG Evaluation of CBT for Obsessive-Compulsive Disorder · NA · active not recruiting
Other Changping Laboratory trials
Trials by the same sponsor.
- NCT06350396 — pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression · NA · recruiting
- NCT06255535 — pBFS Guided rTMS Over Cognitive Control Network for ASD · NA · recruiting
- NCT06255561 — pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression · NA · unknown
- NCT06166082 — Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression · NA · unknown
- NCT06112652 — Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05964049 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changping Laboratory
- Last refreshed: 27 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05964049.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing